Treating non-motor symptoms of Parkinson’s disease with transplantation of stem cells

References

• Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55
   PubMed Web of Science ®Google Scholar
• Braak H, Tredici KD, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197-211
   PubMed Web of Science ®Google Scholar
• Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson’s disease. Biochim Biophys Acta 2009;1792:688-702
   PubMed Web of Science ®Google Scholar
• Riekkinen P, Kejonen K, Laakso MP, et al. Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson’s disease patients. Neuroreport 1998;9:1507-11
   PubMed Web of Science ®Google Scholar
• Bruck A, Kurki T, Kaasinen V, et al. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson’s disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004;75:1467-9
   PubMed Web of Science ®Google Scholar
• Wolters EC, Francot CM. Mental dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 1998;4:107-12
   PubMedGoogle Scholar
• Wolters EC. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2009. Suppl 3):S6-12
   Google Scholar
• Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
   PubMed Web of Science ®Google Scholar
• Graybiel AM. The basal ganglia and cognitive pattern generators. Schizophr Bull 1997;23:459-69
   PubMed Web of Science ®Google Scholar
• Tsui A, Isacson O. Functions of the nigrostrial dopaminergic synapse and the use of neurotransplantation in Parkinson’s disease. J Neurol 2011;258:1393-405
   PubMed Web of Science ®Google Scholar
• Groenewegen HJ. Cortical–subcortical relationships and the limbic forebrain. In: Timble MR, Cummings JL, editors. Contemporary behavioral neurology. Butterworth-Heinemann; Boston: 1997. pp 29-48
   Google Scholar
• Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997;244:2-8
   PubMed Web of Science ®Google Scholar
• Gabrieli JDE, Singh J, Stebbins GT, Goetz CG. Reduced working memory span in Parkinson’s disease: evidence for the role of a frontostriatal system in working and strategic memory. Neuropsychol 1996;10:322-32
   Web of Science ®Google Scholar
• Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson’s disease and its relationship to motor disability. Brain 1991;114:2095-122
   PubMed Web of Science ®Google Scholar
• Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25:2649-53
   PubMed Web of Science ®Google Scholar
• Abdel-Salam OM. Drugs used to treat Parkinson’s disease, present status and future directions. CNS Neurol Disord Drug Targets 2008;7:321-42
   PubMed Web of Science ®Google Scholar
• Young W; Cerebrolysin review. W.M. Keck Center for Collaborative Neuroscience. Available from: http://wiseyoung.wordpress.com/2009/02/10/271/ [Last accessed 24 Oct 2014]
   Google Scholar
• Riley C, Hutter-Paier B, Windisch M, et al. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J Neural Transm 2006;113:103-10
   PubMed Web of Science ®Google Scholar
• Lukhanina EP, Karaban’ IN, Burenok IuA, et al. Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson’s disease. Zh Nevrol Psikhiatr Im S S Korsakova 2004;104:54-60
   PubMedGoogle Scholar
• Higgins B. Parkinson’s Disease. London: Royal College of Physicians 2006
   Google Scholar
• Glavaski-Joksimovic A, Bohn MC. Mesenchymal stem cells and neuroregeneration in Parkinson’s disease. Exp Neurol 2013;247:25-38
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol 2014;4:805-26
   PubMed Web of Science ®Google Scholar
• Borlongan CV, Sanberg PR, Freeman TB. Neural transplantation for neurodegenerative disorders. Lancet 1999;353(Suppl 1):S129-30
   PubMed Web of Science ®Google Scholar
• Lindvall O. Prospects of transplantation in human neurodegenerative diseases. Trends Neurosci 1991;14:376-84
   PubMed Web of Science ®Google Scholar
• Wenning GK, Odin P, Morrish P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease. Ann Neurol 1997;42:95-107
   PubMed Web of Science ®Google Scholar
• Freeman TB, Olanow WC, Hauser RA, et al. Human fetal tissue transplantation. Neurosurgical treatment of movement disorders. Am Assoc Neurolog Surg 1998;177-95
   Google Scholar
• Kordower JH, Freeman TB, Chen EY, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov Dis 1998;13:383-93
   PubMed Web of Science ®Google Scholar
• Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson’s disease. Arch Neurol 1999;56:179-87
   PubMed Web of Science ®Google Scholar
• Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001;344:710-19
   PubMed Web of Science ®Google Scholar
• Hagell P, Piccini P, Björklund A, et al. Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 2002;5:627-8
   PubMed Web of Science ®Google Scholar
• Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403-14
   PubMed Web of Science ®Google Scholar
• Politis M. Dyskinesias after neural transplantation in Parkinson’s disease: what do we know and what is next? BMC Med 2010;8:80
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Loane C, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson’s patients with neural transplants. Sci Transl Med 2010;2:38-46
   Web of Science ®Google Scholar
• Politis M, Loane C, Wu K, et al. Serotonergic mediated body mass index changes in Parkinson’s disease. Neurobiol Dis 2011;43:609-15
   PubMed Web of Science ®Google Scholar
• Piccini P, Pavese N, Hagell P, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson’s disease. Brain 2005;128:2977-86
   PubMed Web of Science ®Google Scholar
• Isacson O, Bjorklund LM, Schumacher JM. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson’s disease by stem cells. Ann Neurol 2003;53:S135-46
   PubMed Web of Science ®Google Scholar
• Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson’s disease: High striatal serotonin/DA transporter ratio. Mov Disord 2011;26:1997-2003
   PubMed Web of Science ®Google Scholar
• Zhao P, Luo Z, Tian W. Solving the puzzle of Parkinson’s disease using induced pluripotent stem cells. Exp Biol Med (Maywood) 2014;239:1421-32
   PubMed Web of Science ®Google Scholar
• Sundberg M, Hallett P, Bogetofte H, et al. Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 2013;31:1548-62
   PubMed Web of Science ®Google Scholar
• Park S, Kim E, Koh SE, et al. Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson’s disease model rats and alleviation of asymmetric rotational behavior. Brain Res 2012;1466:158-66
   PubMed Web of Science ®Google Scholar
• Fricker-Gates RA, Gates MA. Stem cell-derived dopamine neurons for brain repair in Parkinson’s disease. Regen Med 2010;5:267-78
   PubMed Web of Science ®Google Scholar
• Burns TC, Verfaillie CM, Low WC. Stem cells for ischemic brain injury: a critical review. J Comp Neurol 2009;515:125-44
   PubMed Web of Science ®Google Scholar
• Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders-time for clinical translation. J Clin Invest 2010;120:29-40
   PubMed Web of Science ®Google Scholar
• Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Rest 2009;87:2183-200
   PubMed Web of Science ®Google Scholar
• Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004;103:1669-75
   PubMed Web of Science ®Google Scholar
• Weyand B, Dominici M, Hass R, et al. Mesenchymal stem cells: basics and clinical application II. Springer; Heidelberg: 2013
   Google Scholar
• Dezawa M. Insights into autotransplantation: the unexpected discovery of specific induction systems in bone marrow stromal cells. Cell Mol Life Sci 2006;63:2764-72
   PubMed Web of Science ®Google Scholar
• Sanberg PR, Eve DJ, Cruz LE, Borlongan CV. Neurological disorders and the potential role for stem cells as a therapy. Br Med Bull 2012;101:163-81
   PubMed Web of Science ®Google Scholar
• Carrero R, Montero JA, Sepúlveda P, et al. IL1β Induces mesenchymal stem cells migration and leucocyte chemotaxis through NF-κB. Stem Cell Rev 2012;8:905-16
   PubMed Web of Science ®Google Scholar
• Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trend Mol Med 2010;16:203-9
   PubMed Web of Science ®Google Scholar
• Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Diff 2014;21:216-25
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Shingo T, Muraoka K, et al. Neurorescue effects of VEGF on a rat model of Parkinson’s disease. Brain Res 2005;1053:10-18
   PubMed Web of Science ®Google Scholar
• Borlongan CV, Stahl CE, Cameron DF, et al. CNS immunological modulation of neural graft rejection and survival. Neurol Res 1996;18:297-304
   PubMed Web of Science ®Google Scholar
• Borlongan CV, Cameron DF, Saporta S, et al. Intracerebral transplantation of testis- derived sertoli cells promotes functional recovery in female rats with 6-hydroxydopamine-induced hemiparkinsonism. Exp Neurol 1997;148:388-92
   PubMed Web of Science ®Google Scholar
• Mosley RL, Hutter-Saunders J, Stone DK, et al. Inflammation and Adaptive Immunity in Parkinson’s Disease. Cold Spring Harb Perspect Med 2012;2
   Web of Science ®Google Scholar
• Cachope R, Cheer JF. Local control of striatal dopamine release. Front Behav Neurosci 2014;8:188
   PubMed Web of Science ®Google Scholar
• Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000;61:364-70
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9
   PubMed Web of Science ®Google Scholar
• Ahmed HH, Salem AM, Atta HM, et al. Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson’s disease in rat model? Hum Exp Toxicol 2014;33:1217-31
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Matsukawa N, Hara K, et al. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J Neurosci 2006;26:12497-511
   PubMed Web of Science ®Google Scholar
• Jung CG, Hida H, Nakahira K, et al. Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin- positive cells. FASEB J 2004;18:1237-9
   PubMed Web of Science ®Google Scholar
• Goldman S. Stem and progenitor cell-based therapy of the human central nervous system. Nat Biotechnol 2005;23:862-71
   PubMed Web of Science ®Google Scholar
• Rafuse VF, Soundararajan P, Leopold C, Robertson HA. Neuroprotective properties of cultured neural progenitor cells are associated with the production of sonic hedgehog. Neuroscience 2005;131:899-916
   PubMed Web of Science ®Google Scholar
• Ghosh B, Zhang C, Smith GM. Bridging between transplantation therapy and neurotrophic factors in Parkinson’s disease. Front Biosci (Elite Ed) 2014;6:225-35
   PubMedGoogle Scholar
• Venkataramana NK, Kumar SK, Balaraju S, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. Transl Res 2010;155:62-70
   PubMed Web of Science ®Google Scholar
• Redmond DEJr, Bjugstad KB, Teng YD, et al. Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci USA 2007;104:12175-80
   PubMed Web of Science ®Google Scholar
• Teng YD, Lavik EB, Qu X, et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci USA 2002;99:3024-9
   PubMed Web of Science ®Google Scholar
• Song H, Stevens CF, Gage FH. Astroglia induce neurogenesis from adult neural stem cells. Nature 2002;417:39-44
   PubMed Web of Science ®Google Scholar
• Christopherson KS, Ullian EM, Stokes CC, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 2005;120:421-33
   PubMed Web of Science ®Google Scholar
• Aldrin-Kirk P, Davidsson M, Holmqvist S, et al. Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons. PLoS One 2014;9
   PubMed Web of Science ®Google Scholar
• Tsui A, Isacson O. Functions of the nigrostrial dopaminergic synapse and the use of neurotransplantation in Parkinson’s disease. J Neurol 2011;258:1393-405
   PubMed Web of Science ®Google Scholar
• Zhang S, Zou Z, Jiang X, et al. The Therapeutic Effects of Tyrosine Hydroxylase Gene transfected hematopoetic stem cells in a rat model of Parkinson’s disease. Cell Mol Neurobiol 2008;28:529-43
   PubMed Web of Science ®Google Scholar
• Zou Z, Jiang X, Zhang W, et al. Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson’s disease a rat model study. Brain Res 2010;1346:279-86
   PubMed Web of Science ®Google Scholar
• Kurtz A. Mesenchymal stem cell delivery routes and fate. Int J Stem Cells 2008;1:1-7
   PubMedGoogle Scholar
• Lin P, Correa D, Kean TJ, et al. Serial transplantation and long-term engraftment of intra-arterially delivered clonally derived mesenchymal stem cells to injured bone marrow. Mol Ther 2014;22:160-8
   PubMed Web of Science ®Google Scholar
• Pardal R, Lopez-Barneo J. Neural stem cells and transplantation studies in Parkinson’s disease. Adv Exp Med Biol 2012;741:206-16
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235-45
   PubMed Web of Science ®Google Scholar
• Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416-21
   PubMed Web of Science ®Google Scholar
• Politis M, Piccini P. In vivo imaging of the integration and function of nigral grafts in clinical trials. Prog Brain Res 2012;200:199-220
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Loane C, et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with DA grafts. Sci Transl Med 2012;4:128-41
   Google Scholar
• Mukhida K, Brownstone R, Mendez I, et al. A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioral recovery in parkinsonian rats. Brain 2008;131:2106-26
   PubMed Web of Science ®Google Scholar
• O’keeffe FE, Scott SA, Tyers P, et al. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson’s disease. Brain 2008;131:630-41
   PubMed Web of Science ®Google Scholar
• Sanchez-Pernaute R, Lee H, Patterson M, et al. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson’s disease. Brain 2008;131:2127-39
   PubMed Web of Science ®Google Scholar
• Slevin J, Gerhardt G, Smith C, et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2010;102:216-22
   Web of Science ®Google Scholar
• Kohl Z, Winner B, Ubhi K, et al. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 2012;35:10-19
   PubMed Web of Science ®Google Scholar
• Dyson SC, Barker RA. Cell-based therapies for Parkinson’s disease. Expert Rev Neurother 2011;11:831-44
   PubMed Web of Science ®Google Scholar
• Galpern WR, Burns LH, Deacon TW, et al. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson’s disease: functional recovery and graft morphology. Exp Neurol 1996;140:1-13
   PubMed Web of Science ®Google Scholar
• Levivier M, Dethy S, Rodesch F, et al. Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson’s disease. Methodology and 6-month to 1-year follow-up in 3 patients. Stereotact Funct Neurosurg 1997;69:99-111
   PubMed Web of Science ®Google Scholar
• Pardal R, López-Barneo J. Neural stem cells and transplantation studies in Parkinson’s disease. Adv Exp Med Biol 2012;741:206-16
   PubMed Web of Science ®Google Scholar
• Danielyan L, Beer-Hammer S, Stolzing A, et al. Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant 2014;23:123-39
   PubMed Web of Science ®Google Scholar
• Capitelli CS, Lopes CS, Alves AC, et al. Opposite effects of bone marrow-derived cells transplantation in MPTP-rat model of Parkinson’s disease: a comparison study of mononuclear and mesenchymal stem cells. Int J Med Sci 2014;11:1049-64
   PubMed Web of Science ®Google Scholar
• Doi D, Samata B, Katsukawa M, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2014;2:337-50
   PubMed Web of Science ®Google Scholar
• Autologous mesenchymal stem cell transplant for Parkinson’s Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT00976430
   Google Scholar
• Mesenchymal stem cells transplantation to patients with Parkinson’s Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01446614
   Google Scholar
• Study to assess the safety and effects of autologous adipose-derived stromal in patients with Parkinson’s Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01453803
   Google Scholar
• Molecular analysis of human neural stem cells. Available form https://clinicaltrials.gov/ct2/show/NCT01329926
   Google Scholar
• Clinical trial to evaluate bone marrow stem cell therapy for PSP, a rare form of Parkinsonism. Available from: https://clinicaltrials.gov/ct2/show/NCT01824121
   Google Scholar